Capital Fund Management (CFM)
BIO icon

Capital Fund Management (CFM)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Capital Fund Management (CFM)’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,300
Closed -$1.34M – 1665
2019
Q2 		$1.34M Buy
+4,300
New +$1.29M 0.01% 919

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital Fund Management (CFM)'s BIO Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 20,591 shares — an estimated $4.97M sold.

Capital Fund Management (CFM) first reported a position in BIO in Q2 2014 and held it in 6 quarters. The position peaked at $14.2M in Q4 2020. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

  • Capital Fund Management (CFM) reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 20,591 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $4.97M.
  • Capital Fund Management (CFM) first reported a position in Bio-Rad Laboratories Class A in Q2 2014 and held it in 6 quarters.
  • Capital Fund Management (CFM)'s Bio-Rad Laboratories Class A position peaked at $14.2M in Q4 2020.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.